Study links maropitant to lower gastric and jejunal peristalsis

Maropitant citrate, the antiemetic marketed as Cerenia, significantly reduced ultrasonographically measured peristalsis in the pylorus and jejunum of 21 healthy adult dogs in a prospective study published in Veterinary Radiology & Ultrasound, while not significantly changing intestinal diameter or wall thickness. The study adds imaging-based evidence that the drug can slow gastrointestinal motility, at least transiently, without creating the kind of bowel wall or luminal changes that might mimic structural disease on ultrasound or radiographs. Maropitant is widely used in dogs for prevention of acute vomiting and motion sickness, and its approved labeling focuses on antiemetic indications rather than motility effects. (eurekamag.com)

Why it matters: For veterinary professionals, the finding is most relevant when interpreting abdominal imaging in dogs that recently received maropitant. A lower peristaltic rate in the stomach or jejunum could reflect a medication effect rather than primary ileus or progression of gastrointestinal disease, especially in otherwise stable patients. Earlier work has also explored maropitant’s effects on gastric function, including research on gastric emptying in healthy dogs, which supports the broader idea that NK-1 antagonism may influence gastrointestinal physiology beyond emesis control. Taken together, the new study doesn’t argue against using maropitant, but it does suggest clinicians should factor timing of administration into ultrasound interpretation and case workups. (research.ed.ac.uk)

What to watch: The next step is whether follow-up studies in vomiting dogs, dogs with suspected obstruction, or hospitalized patients show that maropitant-related slowing of peristalsis changes diagnostic accuracy or clinical decision-making. (eurekamag.com)